Akums Drugs and Pharmaceuticals, a leading contract development and manufacturing organization (CDMO), has announced the launch of a state-of-the-art sterile manufacturing facility dedicated to producing lyophilised products and injectables. The facility will also produce vials, ampoules, eye and ear drops, and form-fill-seal (FFS) products to meet the rising demand in the global pharmaceutical market.
Expanding into Lyophilisation: A Strategic Move for Akums
Lyophilisation, also known as freeze-drying, is a specialized process of removing water from drug particles at freezing temperatures to preserve the stability, efficacy, and shelf life of sensitive pharmaceutical compounds. This process is particularly critical for drugs that lose potency when exposed to heat or moisture, making it an essential technique in the production of high-quality, long-lasting medications.
With its entry into the lyophilisation segment, Akums is tapping into a niche market with significant growth potential. The company aims to leverage its expertise to address specialized therapeutic needs and cater to the increasing demand for stable and long-lasting pharmaceutical products.
Addressing a Growing Market Opportunity
The global market for lyophilised injectables is projected to grow from $3.37 billion in 2023 to $4.98 billion by 2030, at a compound annual growth rate (CAGR) of 5.6%. This growth is driven by the rising demand for pharmaceutical products that require enhanced stability and extended shelf life.
Akums’ new facility is strategically positioned to capitalize on this growing market trend. By expanding its capabilities in sterile manufacturing, the company aims to meet the evolving needs of the pharmaceutical industry, especially in specialized drug segments that have high entry barriers and limited competition.
“By entering this space, Akums aims to meet the growing global demand for lyophilised products,” the company stated. The advanced facility will enable Akums to manufacture these specialized products at scale, ensuring consistent quality and safety standards.
Focus on Quality and Innovation
The newly operational sterile facility aligns with Akums’ commitment to quality, safety, and innovation. By adopting advanced technologies and adhering to stringent regulatory standards, the company ensures that its products meet the highest industry benchmarks. The facility will support the production of a wide range of therapeutic products, catering to both domestic and international markets.
Sanjeev Jain, Managing Director of Akums Drugs and Pharmaceuticals, commented on the new development: “As global demand for lyophilised drugs continues to grow, our new facility is primed to meet this demand with the highest standards of quality and safety. This expansion reflects our commitment to providing innovative solutions that address the critical needs of the healthcare sector.”
Supporting Large-Scale Manufacturing and Global Expansion
Akums’ focus on capacity expansion comes at a pivotal time as the company continues to strengthen its position in the global pharmaceutical landscape. Following its transition to a public entity in September last year, the CDMO has been actively investing in new infrastructure to enhance its manufacturing capabilities.
The new facility will bolster Akums’ ability to meet the rising global demand for lyophilised products across various therapeutic areas. This move is expected to improve the company’s competitiveness in the international market and solidify its reputation as a trusted partner for pharmaceutical companies worldwide.
A Commitment to Meeting Global Healthcare Needs
By investing in cutting-edge facilities and embracing innovation, Akums is well-positioned to meet the growing global demand for lyophilised and sterile dosage forms. The company’s strategic move into this specialized segment underscores its dedication to addressing critical healthcare challenges and improving patient outcomes.
With the increasing demand for products requiring enhanced stability, Akums is poised to play a pivotal role in shaping the future of pharmaceutical manufacturing. The company’s new facility not only marks a significant milestone in its growth journey but also reinforces its commitment to delivering high-quality, innovative healthcare solutions that meet global standards.